Paragon 28, Inc. (FNA) - צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים

Quarterly EPS growth dynamics demonstrate the resilience of Paragon 28, Inc. (FNA) to economic cycles, as demand for foot implants remains independent of market phases. The metric reached the level of 62.40, supported by surgeons' commitment to unique instrumentation and stable sales of consumables. High product margins and recognition within the medical community ensure a regular cash flow for the company.

This indicator measures the quarterly dynamics of earnings per share, reflecting the rate of change in business profitability following each reporting period. By analyzing the comparison of quarterly EPS, an investor can identify the risk of a price correction during abnormal profit spikes. For Paragon 28, Inc. (FNA), growth in this metric confirms the effectiveness of high sales bonuses and the recruitment of elite orthopedic engineers to advance innovative surgery.